First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.
Sign Up to like & getrecommendations! Published in 2021 at "British journal of cancer"
DOI: 10.1038/s41416-021-01657-7
Abstract: BACKGROUND Interleukin-1 (IL-1) signalling is involved in various protumoural processes including proliferation, immune evasion, metastasis and chemoresistance. CAN04 is a first-in-class monoclonal antibody that binds IL-1 receptor accessory protein (IL1RAP), required for IL-1 signalling. In… read more here.
Keywords: study; phase; antibody; dose ... See more keywords